Takeda Pharmaceutical Company Limited

Altai Republic
Altay region
Amur Oblast
Arkhangelsk region
Astrakhan region
Belgorod region
Bryansk region
Chechen Republic
Chelyabinsk region
Chukotka Autonomous Okrug
Irkutsk region
Ivanovo region
Jewish Autonomous Region
Kaliningrad region
Kaluga region
Kamchatka Krai
Kemerovo region
Khabarovsk Krai
Khanty-Mansi Autonomous Okrug
Kirov region
Komi Republic
Kostroma region
Krasnodar region
Krasnoyarsk Territory
Kurgan region
Kursk region
Leningrad region
Lipetsk region
Magadan region
Moscow region
Murmansk region
Nenets Autonomous Okrug
Nizhny Novgorod region
Novgorod region
Novosibirsk region
Omsk region
Orel region
Orenburg region
Penza region
Perm Krai
Primorsky Krai
Pskov region
Republic of Adygea
Republic of Bashkortostan
Republic of Buryatia
Republic of Chuvashia
Republic of Dagestan
Republic of Ingushetia
Republic of Kabardino-Balkaria
Republic of Kalmykia
Republic of Karachay-Cherkessia
Republic of Karelia
Republic of Khakassia
Republic of Mari El
Republic of Mordovia
Republic of North Ossetia
Republic of Sakha (Yakutia)
Republic of Tatarstan
Republic of Tyva
Rostov region
Ryazan region
Sakhalin Region
Samara region
Saratov region
Smolensk region
St. Petersburg
Stavropol region
Sverdlovsk region
Tambov region
Tomsk Oblast
Trans-Baikal Territory
Tula region
Tver region
Tyumen region
Udmurt Republic
Ulyanovsk region
Vladimir region
Volgograd region
Vologda region
Voronezh region
Yamal-Nenets Autonomous Okrug
Yaroslavl region
Republic of Crimea

Investor profile

Takeda Pharmaceutical Company Limited


Company's website: www.takeda.com

T: +81-3-3278-3256

Public company

E-mail: jeffrey.cross@takeda.com

Contact: Christophe Weber, Representative Director

Takeda Pharmaceutical Company Limited (Takeda) is a research-based global company that primarily focuses on pharmaceuticals. Takeda has an active commercial presence in such therapeutic areas as central nervous system diseases, cardiovascular and metabolic diseases, gastroenterology, oncology and vaccines.  Takeda’s strong presence in North America, Japan and other Asian countries was further supplemented with good positions in Europe and rapidly growing emerging markets following its merger with Nycomed. The merged company is represented in more than 70 countries, ranks fifteenth among the biggest companies in the global pharmaceutical industry and has the world’s seventh largest portfolio of advanced developments.

Takeda Pharmaceutical Company Limited globally
Takeda Pharmaceutical Company Limited in Russia
Takeda Pharmaceutical Company Limited highlights for Russia

1993Nycomed representative office in Russia

2010 – foundation laid for first Nycomed plant in Yaroslavl.

2012 – Yaroslavl plant goes into operation. License obtained.

2012 – Nycomed rebranded as Takeda. Starting 1 January 2013.

2013 – Takeda celebrates 20th anniversary of its operations in Russia.

2014 – Takeda starts R&D cooperation with the Siberian Branch of the Russian Academy of Sciences.

In March 2014, Russia’s healthcare ministry seconds Edarbi drug registration.